• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

38.19 +0.05 (+0.13%)
Streaming Delayed Price Updated: 10:41 AM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 138,629
Open 38.48
Bid (Size) 38.15 (100)
Ask (Size) 38.27 (100)
Prev. Close 38.14
Today's Range 37.75 - 38.54
52wk Range 14.32 - 39.28
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
May 24, 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
May 24, 2026
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+47.4%
+47.4%
1 Month
+16.2%
+16.2%
3 Month
+52.2%
+52.2%
6 Month
+50.2%
+50.2%
1 Year
+136.5%
+136.5%

More News

Read More
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
May 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
Immunovant Inc (NASDAQ:IMVT) Surges 26% Pre-Market on Strong IMVT-1402 Clinical Data Despite Wider Q4 Loss ↗
May 20, 2026
Via Chartmill
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
May 23, 2026
Via The Motley Fool
News headline image
These Analysts Increase Their Forecasts On Immunovant After Q4 Results ↗
May 21, 2026
Via Benzinga
Top movers in Wednesday's session ↗
May 20, 2026
Via Chartmill
News headline image
Immunovant Stock Surges Despite Disappointing Earnings Miss ↗
May 20, 2026
Via Benzinga
Keep an eye on the top gainers and losers in Wednesday's session. ↗
May 20, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
May 20, 2026
Via Chartmill
News headline image
Immunovant Q4 Earnings Call Highlights ↗
May 20, 2026
Via MarketBeat
Topics Earnings
Stay updated with the stocks that are on the move in today's pre-market session. ↗
May 20, 2026
Via Chartmill
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
April 13, 2026
Via MarketMinute
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
April 02, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
March 15, 2026
Via The Motley Fool
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Via Finterra
Topics Economy
News headline image
Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗
March 11, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗
March 11, 2026
Via The Motley Fool
News headline image
Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗
March 11, 2026
Via The Motley Fool
Topics Government
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
February 26, 2026
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗
February 06, 2026
Via The Motley Fool
Topics Earnings
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
Via Finterra
Topics ETFs Economy Initial Public Offering

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?
Yes, Immunovant, Inc. - Common Stock is publicly traded.
What exchange does Immunovant, Inc. - Common Stock trade on?
Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunovant, Inc. - Common Stock?
The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
What is the current price of Immunovant, Inc. - Common Stock?
The current price of Immunovant, Inc. - Common Stock is 38.19
When was Immunovant, Inc. - Common Stock last traded?
The last trade of Immunovant, Inc. - Common Stock was at 07/02/26 10:41 AM ET
What is the market capitalization of Immunovant, Inc. - Common Stock?
The market capitalization of Immunovant, Inc. - Common Stock is 4.39B
How many shares of Immunovant, Inc. - Common Stock are outstanding?
Immunovant, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap